MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Kidney & Renal
Boulevard Bio
Attachments
Precision Immunology for Autoimmune Disease | Boulevard Bio
Parents
*Architects: BioPharmaceuticals_Inflammation, Allergy & Autoimmune
*Architects: Biotechnology _Monoclonal, Polyclonal, Bispecific Antibodies & Antibody-Drug Conjugates (ADC)s
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Kidney & Renal
*Industry: New York
Venture Capital: Angel, Seed & Incubator Series
Children
*BLVD101 bispecific B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) antibody being developed for rare kidney disease IgA nephropathy (IgAN)
2026: Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugs
Co-founded by Austrian researcher and B cell expert Georg Schett, M.D., along with Deerfield Partner and 3DC CEO Frank Nestle, M.D. (2026)
Founded 2026
Mahesh Karande, CEO, Boulevard Bio, former CEO, Omega Therapeutics, former, Novartis (2026)